Robert Ferguson

Robert Ferguson

Auto-generated profile, based on publicly available information

Robert Ferguson

Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Purpose: Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers. Experimental Design: We assessed postsurgical, pre–ICI treatment peripheral CD4+ and CD8+ T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab (n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression. Results: The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4+ cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ2P value = 0.001) with 73% accuracy and was independent of disease recurrence (P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy (χ2P value = 8.91E−06). Conclusions: We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.

1 October 2024
Verified
Other
Open access
PDF file
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Supplementary Figure S5. Detailed annotation for semi-supervised hierarchical clustering of the genes associated with SYK in protein-protein interaction (PPI) analysis comparing TOXlowvs TOXhighin CD4+cells from COMBO-treated patients (n = 78).

1 October 2024
Verified
Other
Open access
PDF file
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Supplementary Figure S7. Waterfall plot for logistic regression model predicting severe (grade 3-5) irAEs using 24-gene SYK GEP.

1 October 2024
Verified
Other
Open access
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Supplementary Table S1. irAE event and grades for the patient population.

1 October 2024
Verified
Other
Open access
PDF file
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Supplementary Figure S6. Correlation plots for predictor variables in cross-validation logistic regression models.

1 October 2024
Verified
Other
Open access
KMKelsey Monson
Kelsey Monson
RFRobert Ferguson
Robert Ferguson
JHJoanna E. Handzlik
Joanna E. Handzlik
JXJiahan Xiong
Jiahan Xiong
SDSasha Dagayev
Sasha Dagayev
TKTomas Kirchhoff
Tomas Kirchhoff
Supplementary Table S6. Gene signature for COMBO CD4+ DEGs in SYK pathway, High vs Low Toxicity.